NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 1.0 %

NBY opened at $0.60 on Wednesday. The stock has a 50-day moving average of $0.65 and a 200 day moving average of $1.22. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $10.23. The firm has a market cap of $2.94 million, a P/E ratio of -0.01 and a beta of 0.69.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.